MRK

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

✗

Return

+2.26%

Status

scored

Trim 25% of MRK via $145-$146 limit orders over 1-2 weeks, preserving 75% core for Q3 earnings reassessment, based on broken momentum stack (MACD bearish cross, RSI 44.96, price below 10 EMA and Bollinger middle band) and elevated cost base concerns tempered by intact defensive ballast (rising 200 SMA, $15.2B TTM FCF, BBB+/A- ratings). Re-engage on $145.65 reclaim with RSI >50 and MACD histogram narrowing; cut residual on confirmed close below $139.53 on volume >8M.

Outcome

✓

Return

-0.29%

Status

scored

Maintain MRK at neutral weight with HOLD rating. The bull case requires four sequential confirmations while the bear case needs only one close below the 50 SMA, making probability-weighted risk/reward approximately 1:1 rather than the aggressive analyst's claimed 1:3. Seven prior Underweight calls on defensive compounders with intact 200 SMA delivered only -0.4% to -2.5% alpha, and the 200 SMA is rising from $112 to $122, so the defensive ballast remains intact.

Outcome

✓

Return

+0.60%

Status

scored

Maintain MRK at the lower end of benchmark weight (0.5-1.0% of portfolio) given the broken short-term momentum stack below the 50 SMA at $142.12. Trim 10-20% on rallies into the $144-146 zone while avoiding aggressive additions below this broken technical level. The Q3 2026 earnings catalyst in mid-to-late October serves as the binding reassessment point.

Outcome

✗

Return

+1.72%

Status

scored

Underweight rating on MRK calls for an immediate 30-40% trim at $143-$145, retaining 50-60% core for the Q3 2026 earnings catalyst. The decision is driven by a broken momentum stack (50 SMA confirmed break, lower Bollinger band punctured at $138.80, MACD at most-negative reading) that the 10/2 lesson identified as requiring half-size reduction before binary catalysts, combined with structural concerns including Keytruda LOE risk on ~40% of revenue, net debt near $47B, and $14B IPR&D write-offs. Hard stop on residual at $121.67 (200 SMA break); warning level at $140 (50 SMA break) triggers cutting residual in half.

Outcome

✗

Return

-3.30%

Status

scored

Maintain MRK at neutral weight with a $141.50 hard stop through the Q3 2026 earnings catalyst; trim 25-30% on a confirmed close above $151.49 on volume >9M, or cut residual in half on a confirmed close below $141.50 on volume >8M. The HOLD is an active, deliberate decision to preserve optionality rather than passive drift, supported by nine prior iterations confirming trim-only-not-exit discipline as the highest expected-value path through binary catalysts.

Outcome

–

Return

+0.34%

Status

scored

Execute a 30% trim immediately at $143-$145 while retaining 50-55% core position, with a $140 warning level triggering a half-position cut on confirmed close and a $134 hard stop. A conditional second tranche is calendared: trim 15-20% on reclaim above $148, or 25-30% on rally to $150-$155 only with positive catalyst confirmation. Q3 2026 earnings (late October) is the binding reassessment point, with the Underweight call driven by Keytruda LOE risk (~24 months, ~35% of revenue), balance sheet deterioration (-$4.63B tangible book value), and dividend yield of 2.34% below the ~4% 10-year Treasury rate.

Outcome

✓

Return

-1.03%

Status

scored

Trim 30-40% of MRK exposure at ~$145 immediately rather than waiting for a $152-$155 bounce that lacks a positive catalyst, while retaining a 50-60% core position to preserve defensive optionality. Re-entry on confirmed stabilization at $136-$141 (50-SMA zone) with MACD histogram positive, RSI >50, and daily close above 10-EMA; hard stop on residual core at $128. The Q3'26 earnings (late October) serves as the binding catalyst reassessment date.

Outcome

✓

Return

-2.66%

Status

scored

Maintain Underweight on MRK with a 30-40% trim targeting 1.5-2% portfolio weight, executing into the $152.64-$155.53 resistance zone on confirmed close above $152.64 with volume >9M. Hold stop at $147.59 for further reduction; hard exit on confirmed close below $140.67 with volume >8M. Q3 2026 earnings (late October) is the binding reassessment date with pre-committed upgrade/downgrade triggers—upgrade requires clean operating EPS ex-IPR&D plus constructive 2027 guidance AND ESMO intismeran efficacy; downgrade to Sell requires confirmed <$140.67 close or balance-sheet impairment.

Outcome

✗

Return

+0.40%

Status

scored

Analysts recommend trimming MRK exposure toward $139.50 on confirmed closes below $140.15 with expanding volume and negative MACD, while new capital should wait for either a pullback to $130–$135 (P/E below ~14x) or a breakout above $155.50 with positive MACD. Position sizing should use a stop at $139.50 (~6% downside), treating rallies to $152.50 and $154 as trimming opportunities rather than entries, with Q3 2026 earnings plus ESMO/BRUNELLO readouts as the binding reassessment point.

Outcome

✓

Return

-0.06%

Status

scored

Maintain MRK at current levels ($148 reference) as the Hold survives its own self-critique—three binding catalysts (Q3 2026 earnings, ESMO intismeran readout, BRUNELLO second pivotal) remain ahead in late October, justifying the wait through resolution rather than preemptive action. The asymmetric risk-reward (5% upside to $155 vs 8.8% downside to $135) fails the confirmation threshold for fresh deployment, and two consecutive zero-alpha Hold reviews demand calibration tightening on pre-committed triggers: trim 25-30% on close >$155.53 (vol >10M) or <$142 (vol >8M), with hard exit below $119 (200 SMA, vol >10M).

Outcome

✓

Return

+0.54%

Status

scored

MRK receives a HOLD rating as three independent analytical frameworks converge on the same directional call. The 91% TSR over 12 months leaves limited upside (~5-8% to $156) against meaningful downside risk (-7% to $138, -20% to $119), with the 15.5x forward P/E already pricing in pipeline execution. Q3 2026 earnings (late October) is the binding catalyst that resolves whether IPR&D charges are non-recurring or structural; pre-committed triggers govern all tactical action through the print. Macro contingency triggers (recession probability >15%, two-hike odds >65%, or 10-year >5.25%) would justify trimming toward the lower end of the 25-30% range.

Outcome

✓

Return

-0.07%

Status

scored

All three risk analysts unanimously arrive at HOLD through independent analytical paths—Aggressive, Conservative, and Neutral—confirming this is a calibration debate rather than a directional one. The strategic plan calls for maintaining current MRK exposure with a tactical trim of 25–30% into confirmed strength above $151.65 on volume >9M shares, while holding the hard stop at $138.16 on a closing basis; do not initiate new longs above $148. The next binding reassessment is Q3 2026 earnings (late October), with ESMO intismeran + Keytruda INTerpath-001 as a near-term catalyst, and expected alpha from this Hold is sub-50bps based on historical convergence patterns.

Outcome

✗

Return

-1.88%

Status

scored

Maintain MRK at current benchmark weight through the late-October catalyst cluster (ESMO intismeran Phase 3 readout + Q3 earnings + SC Keytruda FDA decision) rather than trimming ahead of binding binary events. A defined-risk hedge of 5-10% of position via 3-6 month $140-strike puts addresses single-event gap risk without surrendering upside participation. Re-evaluate immediately following the ESMO readout and Q3 print using pre-committed upgrade/downgrade triggers.

Outcome

✓

Return

+0.94%

Status

scored

Maintain MRK exposure through the 72-hour catalyst cluster without adding or trimming; a hard stop at $137 on a closing basis invalidates the medium-term uptrend. The only acceptable tactical deviation is the Neutral analyst's defined-risk hedge (5-10% of position via long-dated puts at $141 strike) to address single-event gap risk without forcing a trim. Re-evaluate immediately following the ESMO intismeran readout on September 23 and the FDA decision print, with Q3 2026 earnings as the binding reassessment date for sizing and rating decisions.

Outcome

✗

Return

+1.79%

Status

scored

Analysts unanimously recommend Hold for MRK at $147-148, rejecting both the aggressive analyst's push to add near $149 resistance and the conservative analyst's 25-30% trim proposal. The decision anchors on $137 (50 SMA structural support) as the hard stop, with $148.10 as the confirmed add trigger pending MACD histogram confirmation, making Q3 2026 late-October earnings the binding reassessment catalyst.

Outcome

✓

Return

-0.19%

Status

scored

Maintain MRK position with a stop at $138.50 (below the lower Bollinger at $141.57), as the stock sits under $148.10 resistance with an active bearish MACD crossover; a capped tactical add of ~25% of base size is only warranted on a confirmed close above $148.10 with volume exceeding 9M shares, with a hard stop on closes below the 10 EMA at $145.83. Q3 2026 earnings (late October) is the binding reassessment catalyst for both sizing and rating decisions.

Outcome

✗

Return

+1.55%

Status

scored

Analysts unanimously recommend trimming ~40% of MRK exposure into the $148–$150 rally zone, retaining 60% core for dividend carry and defensive ballast. Key concerns include Ivonescimab's threat to Keytruda's NSCLC franchise, patent cliff risks, hawkish Fed regime compressing pipeline NPV, and confirmed technical deterioration (MACD histogram at -1.39, RSI bearish divergence). Re-entry requires close above 10 EMA (~$145.54) with MACD histogram compression—not a predetermined price target like $130, which is deemed market-timing on a 0.226-beta name with rising 50 SMA.

Outcome

✗

Return

+0.78%

Status

scored

Trim ~40% of MRK over 1-2 weeks by selling into bounces toward $145-$148 but not waiting for them; if price closes below $140 on volume >8M, accelerate the trim rather than defend. Redeploy proceeds into short-duration Treasuries (~5% risk-free carry), not extended pharma names like LLY. Retain ~60% core exposure with a hard stop at $139.43 (lower Bollinger), and pre-commit to Q3 2026 earnings (late October) as the binding reassessment point.

Outcome

–

Return

-0.73%

Status

scored

Trim 30-35% of MRK position (layered: 20% at $148, 10-15% at $150) into the $148-$150 resistance band to reduce drawdown exposure through the integration window, while holding 65-70% core for Q3 2026 earnings catalyst; hard stop on remaining position at $141.50 with re-entry requiring price reclaim of $148 with volume >9M shares plus either RSI >55 or MACD histogram compressing.

Outcome

✓

Return

+0.64%

Status

scored

All three risk analysts converge on HOLD at ~$143.93, maintaining existing MRK exposure given intact long-term structural pillars (forward P/E 15x on $9.55 normalized consensus, $15B+ FCF run-rate, AAA-/A+ credit, 0.226 beta) but unfavorable short-term asymmetry (upside to trim zone +2.1% to +5.6% vs. downside to invalidation -17.7%, roughly 1:3.5 R/R). The framework sets tiered add zones at $138 and $135.88-$136, trim zone at $147-$152, and hard stop at $118.49, with rating contingent on Q3 2026 earnings (late October) and 2028 Keytruda LOE clarity.

Outcome

✓

Return

-0.54%

Status

scored

Analysts trim MRK to 60% of benchmark weight at $144.71, citing patent cliff math, 52% YoY debt growth to $18.5B, confirmed technical deterioration with MACD below signal, and 93% no-cut probability on Polymarket. Re-entry requires forward P/E compression below 13x (~$124-128), breakout above $156.92 with volume >9M, or pullback to $115-125 with momentum reset.

Outcome

✓

Return

-1.91%

Status

scored

Trim 25-30% of MRK exposure layered into $150-$156 resistance (15% at $150-153, remainder at $155-156) with structural stop at $135 (50 SMA) and tactical invalidation on close below $144.90 with volume >8M. Re-engage only on confirmed breakout above $156.92 with positive MACD histogram or controlled pullback to $138-$142 with momentum reset. This is a 30-90 day tactical trim—fundamentals remain intact but entry management at top of 52-week range into hawkish Fed is unfavorable.

Outcome

–

Return

-0.63%

Status

scored

Initiate MRK Overweight with a measured three-tranche accumulation structure capped at 2.5-3% total allocation, starting with a 0.75% initial tranche at ~$148.50 and an opportunistic second tranche triggered by 50 SMA reclaim, 20 SMA reclaim, or breakout. The blended cost basis across all tranches targets ~1.5:1 risk-reward with a structural stop at $127.50 and a $162 price target on 6-12 month horizon, acknowledging that the single-tranche risk-reward of 0.65:1 ($21 risk vs $13.62 upside to upper Bollinger) is insufficient on its own and only the tiered structure justifies the position.

Outcome

✓

Return

-1.24%

Status

scored

Maintain MRK at current position size with pre-committed triggers for both directions; scale in 1.0-1.5% on confirmed daily close above $156.45 with volume >10M, trim 15-20% on close below $145.75 with capital reserved for $134.59/$117.44 structural re-entry zones, and hard stop at $134.59 (50 SMA).

Outcome

–

Return

-1.32%

Status

scored

Trim 25-35% of the MRK position at $152.34 to reduce concentration risk ahead of a binary Q3 earnings event while preserving optionality on the INTerpath-001 catalyst and defensive FCF profile; set a structural stop at $144.90 with a volume filter >8M to invalidate the post-gap thesis, and hard-cap the residual at 50% of normal mega-cap pharma allocation with re-entry triggers at $156.92 breakout (RSI >70, volume >9M) or pullback to the 10 EMA at $149.32 on declining volume.

Outcome

–

Return

+0.46%

Status

scored

Initiate MRK Overweight with a measured 1.0% initial tranche near $148.55, capped at 2.5% total exposure. Resolve the add/stop incoherence by eliminating the overlapping $147.76–$148.55 add zone and instead defining two non-overlapping triggers: a breakout add above $156.45 on volume >12M and a dip add on a pullback holding $144, with pre-committed trim triggers and a hard stop at $141.

Outcome

✓

Return

+1.19%

Status

scored

Analysts maintain Hold on MRK at $147.50, arguing that trim/Underweight calls are alpha-destructive absent decisive breakdown below $139 or fresh fundamental deterioration. The 8/31 lesson is binding: when price target sits within 2% of entry and structural pillars remain intact, aggressive trimming repeats the 0.66:1 R/R failure pattern. Pre-committed triggers include downside trim (close below 10 EMA at $147.40 on volume >8M, trim 15-20%) and upside trim (close above $158-162 on volume >10M, trim 10-15%), with hard stop at $129 and re-entry zone $131-145 only after confirmed stabilization.

Outcome

✓

Return

+1.42%

Status

scored

Maintain Hold on MRK at current levels ($147-148) with mechanically defined entry and exit triggers, preserving the existing 3-4% defensive exposure without initiating new positions given the 10 EMA proximity ($147.40) and near-term MACD bearish crossover risk. Upgrade to Overweight only on confirmed close above $156 with volume >10M, and trim 10-15% if price closes below the 10 EMA with MACD bearish crossover confirmed, using $139 stop-loss (2x ATR) rather than the tighter $143 level deemed inappropriate for the 4.34 ATR.

Outcome

✓

Return

-0.40%

Status

scored

Maintain MRK at HOLD given a genuine equilibrium between bullish catalyst potential (INTerpath-001 Phase 3 success, $15B FCF, 0.21 beta, Keytruda runway through 2028) and bearish current-state pressures (PEG at 10.7 at 96th percentile, technical compression with ATR expanded 34%, MACD histogram compressed 60%, $24.6B M&A deployment in one quarter). Pre-commit 10-15% trim triggers on close below $147.52 on volume >8M (downside) and above $156 on volume >10M (upside), add only on confirmed technical structure meeting three conditions at $144.90, and size at lower end of defensive range through September 16 FOMC and INTerpath-001 detailed data print.

Outcome

✓

Return

-0.80%

Status

scored

Analysts maintain HOLD on MRK at $149.54, converging on an equilibrium view rather than fence-sitting. The 7% upside to upper Bollinger ($159.53) versus 30-40% downside on INTerpath-001 Phase 3 disappointment creates unfavorable asymmetry for fresh capital, requiring a higher-low confirmation above the 50 SMA ($138-142) with RSI below 50 before adding. A 1.5-2x ATR closing stop at $140-142 tightens risk, while a pre-committed downside trim (25-33% reduction on close below $147.34 on volume >8M) and upside breakout trigger ($159.53+ on volume >10M upgrading to Overweight) structure the tactical plan around the 30-60 day binary catalyst window.

Outcome

✗

Return

-2.33%

Status

scored

Maintain MRK at Overweight with target 1.0-1.25x benchmark weight despite near-term extension risk (RSI 71, ATR expanded 37%, stock at 96% of 52-week high). Stage accumulation across three tranches: 40% at $146-150 stabilization, 30% above $152-153 with volume confirmation, and 30% on catalyst validation. Hard stop at $146.85 with 10-15% pre-committed trim trigger at $158-162, per 8/24 binding lesson on catalyst-aware sizing.

Outcome

✓

Return

-2.14%

Status

scored

Maintain the existing 3-4% MRK position at $156 as Hold reflects intact structural pillars ($15.17B FCF, beta 0.21, Keytruda through 2028) combined with stretched near-term technicals (RSI 77.6, above upper Bollinger Band). Pre-committed trim of 10-15% triggered on any extension to $158-162; pre-committed add of 1-2% only on confirmed pullback to $140-145 with daily close holding the 10 EMA. Trailing stop tightened to $138, hard stop at $129.

Outcome

✗

Return

+3.84%

Status

scored

Underweight rating on MRK with a 25-40% trim recommended into the $150-154 zone (current price $150.66), as the failed Aug 21 retest at $154.49 and declining volume signal distribution; retain 50-65% core for late-October ESMO optionality and the longer-term Keytruda franchise thesis. Hard invalidation sits at a daily close above $154.50 on volume >20M, with re-entry targeted at $135-143 on RSI reset toward 55-60; valuation at $124-134 (12-22% below current) supports the tactical reduction despite $15B+ TTM FCF and 0.21 beta supporting the core holding.

Outcome

✓

Return

-1.24%

Status

scored

Hold MRK at $152 as existing positions should be maintained with a trailing stop at $143.73, while new positions should not be initiated until the $134-141 zone with RSI reset to 50-60; trim 25-33% only if overweight versus mandate, with a hard stop at $127 (50 SMA).

Outcome

✓

Return

+2.39%

Status

scored

The MRK position is maintained at HOLD as all three analysts converge on this decision, supported by an intact structural floor ($15.2B TTM FCF covering interest 29x, 2.23% dividend yield) and a genuine catalyst from Moderna's first positive Phase 3 mRNA cancer vaccine readout. A pre-committed trim of 25-33% is triggered on any retest of $152-154, while staged add opportunities are conditioned on pullback to $138-143 with 2-3 session stabilization and RSI reset to 55-60; the aggressive analyst's $143-145 shallow dip proposal is rejected due to insufficient 1.1-1.4 ATR cushion.

Outcome

✓

Return

-2.11%

Status

scored

Maintain Hold rating on MRK with no trim despite extreme technical readings (RSI 83, 9% above upper Bollinger Band) after the binding 8/18 reflection revealed that mechanical trim-defaults destroy compounding during regime turns; the +12.6% single-session spike validates staying exposed to the Phase 3 mRNA cancer vaccine catalyst. Rather than chasing at current levels ($152), engage via sell cash-secured puts at $140-145 strikes for Oct/Nov expiry to earn premium while awaiting better entry risk/reward, with staged adds targeted in the $135-143 zone.

Outcome

✗

Return

+12.60%

Status

scored

Merck maintains a HOLD rating with a mandatory 10-15% mechanical trim at current levels ($135-137), as the structural floor (TTM FCF of $15.17B, 28-29x interest coverage, 2.61% dividend yield, beta 0.21) justifies continued ownership, but elevated valuation with net debt up 46% YoY to $34.77B, distribution signatures on declining volume, and the 2028 patent cliff warrant reducing concentration near the upper Bollinger Band. Trim proceeds will be redeployed via a three-tranche staged framework anchored at $131-133, $126-128, and $140 breakout respectively, with a hard stop at $122.

Outcome

✓

Return

-0.59%

Status

scored

Hold MRK at $135.97 with benchmark weight as the $135.97 action represents a rejection candle at resistance ($1.18 below $137.15 session high, below upper Bollinger Band at $136.10) on below-average volume of 5.6M shares versus the 10-12M norm. Trim 10-15% into any chase above $137.15 on thin volume; add only on pullback to $130-132 confluence zone or confirmed breakout above $137.15 with ≥8M shares and MACD confirmation.

Outcome

✗

Return

+0.10%

Status

scored

Trim MRK by 20-25% at current levels ($135-136) to reduce from ~3% benchmark weight to ~1.8-2.0% portfolio weight; this is the mechanical enforcement of the prior framework's trim-to-redeploy directive, ending five consecutive Hold reflections that failed to execute. Hard stop at $125 (50 SMA), with conditional re-entry on pullback to $124-126 with stabilizing estimates or breakout above $140 with volume >10M and MACD bullish re-cross; mandatory 30-45 day tactical re-evaluation.

Outcome

✓

Return

+0.21%

Status

scored

Maintain MRK at benchmark weight as three-analyst Hold consensus validates the rating as genuine equilibrium. Do not add at $135.55 given asymmetric risk-reward (3.3-14.4% upside vs. 7.9-17% downside), but retain core exposure for structural FCF and Keytruda franchise support through 2028. Enforce mandatory 30-45 day tactical re-evaluation and trim 25-30% on any rally to $140-145, with hard stop at $122.

Outcome

✗

Return

+1.98%

Status

scored

Hold MRK at the lower end of neutral weight with a $124.50 trailing stop while awaiting entry triggers at $115-118 (200 SMA structural zone) or confirmed breakout above $134 with volume and MACD recross. The 6-12 month structural view remains intact ($15.17B TTM FCF, 13.9x forward P/E) but near-term risk-reward asymmetry (1:3.5 in bears' favor from current $132.92) and mandatory 30-45 day tactical re-evaluation prevent aggressive positioning.

Outcome

✗

Return

+1.92%

Status

scored

Hold MRK at current weight with a $127 trailing stop and 30-45 day time-boxed re-evaluation; maintain core exposure for the structural thesis (15B FCF, 8.4B covered dividend, 0.21 beta) but do not add at 130 levels where MACD bearish cross, upper-Bollinger rejection, and falling consensus estimates create unfavorable risk/reward. Re-engagement triggers include breakout above 133.11 on >7M volume with MACD bullish re-cross, or pullback to 124-125 with positive MACD divergence.

Outcome

✓

Return

-0.38%

Status

scored

Maintain existing MRK core holdings while awaiting technical confirmation; current levels near $130.92 lack sufficient volume (3.82M) to justify new capital deployment given three failed attempts at $133.78 resistance. Initiate 2-3% position adds on pullback to the $122–125 Bollinger/200 SMA confluence zone with rising momentum, or on confirmed breakout above $135.05 with volume exceeding 10M shares. Trailing stop at $128.20 (Bollinger middle band) with hard stop at $120.00; re-evaluate in 30-45 days given unresolved MACD divergence and oscillator divergence signals.

Outcome

✗

Return

+1.82%

Status

scored

Maintain MRK core position at Hold rating with a trailing stop at $122 (below the 50 SMA at $123.65) to manage downside risk while preserving upside exposure. Optional 10-15% trim is acceptable to lock in the +65% Y/Y gain, but a full SELL reduction is not warranted given the intact uptrend (+15.3% above 200 SMA) and absence of confirmed distribution signature. No pharma rotation recommended—any capital from trims should go to cash or a healthcare ETF instead.